Market Place
Sourcing Support
Immunovant Q3 2024 Results & Development Updates
07 Nov 2024 //
GLOBENEWSWIRE
Immunovant to Present Phase 2 Graves’ Disease Data at ATA Meeting
29 Oct 2024 //
GLOBENEWSWIRE
Immunovant Provides Update on Graves’ Disease Development Program
09 Sep 2024 //
GLOBENEWSWIRE
Immunovant To Host Graves` Disease Program Update
05 Sep 2024 //
GLOBENEWSWIRE
Roivant Reports Q1 2025 Financial Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Immunovant Reports Q2 2024 Results And Corporate Updates
06 Aug 2024 //
GLOBENEWSWIRE
Immunovant Delays Trial Readouts To Prioritize Another FcRn Drug
30 May 2024 //
ENDPTS
Immunovant Q4 2024 Results, Corporate Update
29 May 2024 //
GLOBENEWSWIRE
What Makes Immunovant (IMVT) a New Buy Stock
17 Apr 2024 //
YAHOO FINANCE
Immunovant Awarded U.S. Patent for IMVT-1402
12 Mar 2024 //
GLOBENEWSWIRE
Immunovant Reports Financial Results
12 Feb 2024 //
GLOBENEWSWIRE
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Immunovant unveils positive early data for PhII Graves` disease drug
21 Dec 2023 //
ENDPTS
Immunovant posts midphase FcRn data in Graves’, plots next steps
21 Dec 2023 //
FIERCE BIOTECH
Immunovant Reports Positive Phase 2 Results for Batoclimab in Graves™ Disease
20 Dec 2023 //
GLOBENEWSWIRE
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results
28 Nov 2023 //
GLOBENEWSWIRE
Immunovant to Present at Upcoming Investor Conferences
13 Nov 2023 //
GLOBENEWSWIRE
Immunovant Reports Financial Results for the Quarter Ended September 30, 2023
09 Nov 2023 //
GLOBENEWSWIRE
Immunovant Announces Closing of Upsized Common Stock Financing
02 Oct 2023 //
GLOBENEWSWIRE
Immunovant Announces Pricing of $450 Million Common Stock Financing
27 Sep 2023 //
GLOBENEWSWIRE
Immunovant shares surge as early antibody treatment data beats expectations
27 Sep 2023 //
REUTERS
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD
26 Sep 2023 //
GLOBENEWSWIRE
Immunovant Announces Proposed Offering of $300 Million of Common Stock
26 Sep 2023 //
GLOBENEWSWIRE
Immunovant to Host Conference to Report Initial IMVT-1402 Phase 1 Results
25 Sep 2023 //
GLOBENEWSWIRE
Immunovant Reports Financial Results for the Quarter Ended June 30, 2023
10 Aug 2023 //
GLOBENEWSWIRE
Immunovant Stock: With Anti-FcRn Validation Continuing, This Is A Must-Watch
19 Jul 2023 //
SEEKING ALPHA
Immunovant`s FcRn Strategy Gains Momentum
16 Jul 2023 //
MARKETS BUSINESS
Immunovant Reports Financial Results for the Fourth Quarter Ended March 31, 2023
22 May 2023 //
GLOBENEWSWIRE
Immunovant Reports Financial Results for the Quarter
03 Feb 2023 //
GLOBENEWSWIRE
Immunovant Reports Financial Results and Recent Business Updates for the Quarter
04 Nov 2022 //
GLOBENEWSWIRE
Why Immunovant Stock Is Skyrocketing This Week
06 Oct 2022 //
FOOL
Immunovant Announces Pricing of $75.0 Million Underwritten Offering
04 Oct 2022 //
GLOBENEWSWIRE
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
28 Sep 2022 //
GLOBENEWSWIRE
Immunovant to Present at the H.C. Wainwright Global Investment Conference
09 Sep 2022 //
GLOBENEWSWIRE
Immunovant plans to develop batoclimab in CIDP and Graves’ disease
08 Sep 2022 //
PHARMABIZ
Immunovant Announces Two New Development Programs for Batoclimab
07 Sep 2022 //
GLOBENEWSWIRE
UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab
07 Sep 2022 //
GLOBENEWSWIRE
Immunovant to Host Webcast to Announce Two New Indications for Batoclimab
24 Aug 2022 //
GLOBENEWSWIRE
Immunovant Fiscal Q1 Net Loss Widens; Cash Balance Provides Runway Into 2025
05 Aug 2022 //
MARKETSCREENER
Immunovant Reports Financial Results for the Quarter Ended June 30, 2022
05 Aug 2022 //
GLOBENEWSWIRE
Immunovant Achieves Alignment with FDA for PIII Trials of Batoclimab in TED
08 Jun 2022 //
GLOBENEWSWIRE
Immunovant to Report Q4 and FY 2022 Financial Results
06 Jun 2022 //
GLOBENEWSWIRE
Immunovant to Present at the H.C. Wainwright Global Investment Conference
23 May 2022 //
GLOBENEWSWIRE
Immunovant to Present at the UBS Global Healthcare Conference on May 23rd
19 May 2022 //
GLOBENEWSWIRE
Immunovant to Present at LifeSci Partners Immunology and Inflammation Symposium
04 May 2022 //
GLOBENEWSWIRE
Immunovant to Host Virtual R&D Day on March 30, 2022
28 Mar 2022 //
GLOBENEWSWIRE
Immunovant to Present at the 11th Annual SVB Leerink Conference
09 Feb 2022 //
GLOBENEWSWIRE
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
04 Feb 2022 //
GLOBENEWSWIRE
Immunovant Provides Regulatory Update Regarding of Ph3 Trial for Batoclimab
30 Dec 2021 //
GLOBENEWSWIRE
Immunovant Provides Regulatory Update Initiation of Ph3 Trial for Batoclimab
30 Dec 2021 //
IMMUNOVANT
Immunovant Reports Financial Results for the Quarter Ended September 30, 2021
05 Nov 2021 //
GLOBENEWSWIRE
Immunovant Appoints Renee Barnett as Chief Financial Officer
15 Sep 2021 //
GLOBENEWSWIRE
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
09 Aug 2021 //
GLOBENEWSWIRE
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021
09 Aug 2021 //
GLOBENEWSWIRE
Immunovant to Report Financial Results for Quarter Ended June 30, 2021
06 Aug 2021 //
GLOBENEWSWIRE
Roivant ditches plan to reacquire Immunovant, invests $200M
03 Aug 2021 //
FIERCEBIOTECH
Immunovant shares nosedive after lead drug hits more turbulence
02 Jun 2021 //
FIERCE BIOTECH
Roivant, in an unexSPACted twist, wants to reacquire Immunovant
21 May 2021 //
FIERCEBIOTECH
Immunovant stock loses half its value after pausing dosing in trial
02 Feb 2021 //
MARKET WATCH
Immunovant voluntarily halts studies on sole drug after surprise cholesterol
02 Feb 2021 //
ENDPTS
